PHARMACY

Lilly acquires rights for hypogonadism treatment Axiron

BY Alaric DeArment

INDIANAPOLIS Eli Lilly has acquired rights to a testosterone treatment from an Australian manufacturer, the drug maker announced this week.

Lilly said it bought a global license for Axiron from Melbourne, Australia-based Acrux for $50 million, plus up to $285 million in transfer and milestone payments, as well as potential royalties. A regulatory filing for the drug is under review by the Food and Drug Administration. The drug is used to treat testosterone deficiency in men, also known as hypogonadism.

“The addition of Axiron reinforces Lilly’s commitment to men’s health and, if approved, could provide a new treatment option for men suffering from low testosterone,” Lilly Bio-Medicines president Bryce Carmine said. “Lilly hopes to leverage our experience in men’s health to advance both the science and clinical outcomes for men with low testosterone.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

PositiveID releases white paper about the health, economic burdens of diabetes

BY Allison Cerra

DELRAY BEACH, Fla. PositiveID has published a white paper that describes the health and economic burden of diabetes on Americans and the U.S. economy, the company said Wednesday.

“Fixing the Black Hole in Diabetes Management” discusses how patient care and overall health improves when there is a high quality of patient-clinician collaboration. Additionally, PositiveID noted that diabetics who follow recommended self-monitoring blood-glucose testing-level guidelines may not share the test results with their healthcare providers — the test results are not being used to improve glycemic control and achieve long-term goals, thus getting lost in a “black hole.”

PositiveID pointed out that the use of such monitoring systems as its iGlucose system, which uses wireless SMS messaging to automatically communicate a diabetic’s glucose levels in real-time, can be beneficial to diabetic patients. Citing a a 2009 study, “Excessive Hospitalizations and Its Associated Economic Burden among People with Diabetes in the United States,” found that in 2005, hospital charges alone and medical costs for individuals with diabetes exceeded $171 billion and $90 billion, respectively.

Scott Silverman, PositiveID chairman and CEO said, “We believe the benefits of the iGlucose system are obvious. It can provide improved health outcomes through real-time disease management, simplifying patients’ lives and enhancing vital communication between patients and their healthcare providers. iGlucose also has the ability to decrease fraud and healthcare costs for providers and insurers by automatically creating compliant patient testing logs, which are required to comply with Medicare Part B reimbursement regulations.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Pending court ruling, Teva to delay marketing Temodar generic

BY Alaric DeArment

JERUSALEM Teva Pharmaceutical Industries will start marketing its version of a brain tumor drug only if the Federal Circuit of the U.S. District Court upholds a ruling that declared the branded version’s patent unenforceable, Teva announced Wednesday.

The generic drug maker said it had entered an agreement with Schering, now part of Merck & Co., whereby it will market the drug only if the Federal Circuit upholds the U.S. District Court for the District of Delaware’s January ruling that would allow Teva to market a generic version of Schering’s Temodar (temozolomide). The regulatory approval application for the drug was originally filed by Barr Labs, which Teva acquired in 2008.

The agreement also gives Teva to begin selling its version of the drug in August 2013.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES